
Domenico Prisco

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6122347/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Behçet syndrome in children and adults: discovering similarities and differences by a comparative study. Rheumatology, 2023, 62, SI189-SI195.	1.9	2
2	Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial—comment on: â€~Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou <i>et al</i> . Annals of the Rheumatic Diseases, 2022, 81, e140-e140.	0.9	9
3	A unique circulating miRNA profile highlights thrombo-inflammation in Behçet's syndrome. Annals of the Rheumatic Diseases, 2022, 81, 386-397.	0.9	17
4	Sixteen years with Internal and Emergency Medicine: farewell of the Editor-in-Chief. Internal and Emergency Medicine, 2022, 17, 1-2.	2.0	1
5	"In Less than No Time― Feasibility of Rotational Thromboelastometry to Detect Anticoagulant Drugs Activity and to Guide Reversal Therapy. Journal of Clinical Medicine, 2022, 11, 1407.	2.4	14
6	Antithrombotic treatment of retinal vein occlusion: a position statement from the Italian Society on Thrombosis and Haemostasis (SISET) Blood Transfusion, 2022, , .	0.4	2
7	Poststroke Detection of Subclinical Paroxysmal Atrial Fibrillation in Patients With Embolic Stroke of Undetermined Source in the Real World Practice. Neurologist, 2022, Publish Ahead of Print, .	0.7	2
8	Gut Microbiota and Associated Mucosal Immune Response in Eosinophilic Granulomatosis with Polyangiitis (EGPA). Biomedicines, 2022, 10, 1227.	3.2	4
9	Butyrate-Rich Diets Improve Redox Status and Fibrin Lysis in Behçet's Syndrome. Circulation Research, 2021, 128, 278-280.	4.5	31
10	Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Twoâ€year outcomes after the study closure. Journal of Thrombosis and Haemostasis, 2021, 19, 531-535.	3.8	40
11	Comment on: Obstetric antiphospholipid syndrome is not associated with an increased risk of subclinical atherosclerosis. Reply. Rheumatology, 2021, 60, e260-e261.	1.9	0
12	Cardiac involvement in eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss) Tj ETQq0 0 0 rgB Medicine, 2021, 85, 68-79.	T /Overlocl 2.2	k 10 Tf 50 30 14
13	Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome). European Respiratory Journal, 2021, 57, 2004158.	6.7	19
14	Incidence of deep vein thrombosis through an ultrasound surveillance protocol in patients with COVID-19 pneumonia in non-ICU setting: A multicenter prospective study. PLoS ONE, 2021, 16, e0251966.	2.5	20
15	An Insight into Giant Cell Arteritis Pathogenesis: Evidence for Oxidative Stress and SIRT1 Downregulation. Antioxidants, 2021, 10, 885.	5.1	7
16	Questions about COVID-19 associated coagulopathy: possible answers from the viscoelastic tests. Journal of Clinical Monitoring and Computing, 2021, , 1.	1.6	8
17	Neutrophil-mediated mechanisms of damage and <i>in-vitro</i> protective effect of colchicine in non-vascular Behçet's syndrome. Clinical and Experimental Immunology, 2021, 206, 410-421.	2.6	24
18	Circulating miRNome profiling data in Behçet's syndrome. Data in Brief, 2021, 38, 107435.	1.0	3

#	Article	IF	CITATIONS
19	Comparison of treatments for the prevention of fetal growth restriction in obstetric antiphospholipid syndrome: a systematic review and network meta-analysis. Internal and Emergency Medicine, 2021, 16, 1357-1367.	2.0	7
20	Prevalence and clinical course of SARS-CoV-2 infection in patients with Behçet's syndrome. Clinical and Experimental Rheumatology, 2021, 39 Suppl 132, 47-50.	0.8	4
21	Prevalence and clinical course of SARS-CoV-2 infection in patients with Behçet's syndrome. Clinical and Experimental Rheumatology, 2021, 39, 47-50.	0.8	7
22	Management of oral anticoagulation in very old patients with non valvular atrial fibrillation related acute ischemic stroke. Journal of Thrombosis and Thrombolysis, 2020, 49, 86-93.	2.1	7
23	Circulating endothelial and progenitor cells in age-related macular degeneration. European Journal of Ophthalmology, 2020, 30, 956-965.	1.3	1
24	A double-edged sword: e-cigarettes, and other electronic nicotine delivery systems (ENDS): reply. Internal and Emergency Medicine, 2020, 15, 1119-1121.	2.0	7
25	Rituximab for chronic periaortitis without evidence of IgG4-related disease: a long-term follow-up study of 20 patients. Annals of the Rheumatic Diseases, 2020, 79, 433-434.	0.9	19
26	Intravenous immunoglobulin for the secondary prevention of stillbirth in obstetric antiphospholipid syndrome: A case series and systematic review of literature. Autoimmunity Reviews, 2020, 19, 102620.	5.8	8
27	Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular BehA§et's phenotype: a multicentre study. Annals of the Rheumatic Diseases, 2020, 79, 1098-1104.	0.9	39
28	Obstetric antiphospholipid syndrome is not associated with an increased risk of subclinical atherosclerosis. Rheumatology, 2020, 59, 3709-3716.	1.9	12
29	Antiarrhythmic efficacy of anakinra in a young patient with autoimmune lymphocytic myocarditis. Rheumatology, 2020, 59, e88-e90.	1.9	8
30	Behçet: the syndrome. Rheumatology, 2020, 59, iii101-iii107.	1.9	67
31	Significant and Conflicting Correlation of IL-9 With Prevotella and Bacteroides in Human Colorectal Cancer. Frontiers in Immunology, 2020, 11, 573158.	4.8	37
32	Oxidative Stress as a Thrombophilic Factor in Behçet Syndrome. , 2020, , 201-208.		0
33	Subclinical atherosclerosis in asymptomatic carriers of persistent antiphospholipid antibodies positivity: A cross-sectional study. International Journal of Cardiology, 2019, 274, 1-6.	1.7	32
34	Health impact of electronic cigarettes and heated tobacco systems. Internal and Emergency Medicine, 2019, 14, 817-820.	2.0	23
35	Behçet's syndrome: focus on pathogenetic background, clinical phenotypes and specific treatments. Internal and Emergency Medicine, 2019, 14, 639-643.	2.0	9
36	Behçet's Syndrome as a Model of Thrombo-Inflammation: The Role of Neutrophils. Frontiers in Immunology, 2019, 10, 1085.	4.8	79

#	Article	IF	CITATIONS
37	Differential Responses of Colorectal Cancer Cell Lines to Enterococcus faecalis' Strains Isolated from Healthy Donors and Colorectal Cancer Patients. Journal of Clinical Medicine, 2019, 8, 388.	2.4	28
38	Interleukin-17/Interleukin-21 and Interferon-Î ³ producing T cells specific for Î ² 2 Glycoprotein I in atherosclerosis inflammation of systemic lupus erythematosus patients with antiphospholipid syndrome. Haematologica, 2019, 104, 2519-2527.	3.5	19
39	Stem-Cell-Derived Circulating Progenitors Dysfunction in Behçet's Syndrome Patients Correlates With Oxidative Stress. Frontiers in Immunology, 2019, 10, 2877.	4.8	11
40	Treating the Different Phenotypes of Behçet's Syndrome. Frontiers in Immunology, 2019, 10, 2830.	4.8	50
41	Behçet's disease as a cause of cerebral sinus vein thrombosis: an emerging role. Rheumatology, 2019, 58, 563-564.	1.9	4
42	Behçet's syndrome as a tool to dissect the mechanisms of thrombo-inflammation: clinical and pathogenetic aspects. Clinical and Experimental Immunology, 2019, 195, 322-333.	2.6	41
43	Long-term effectiveness and safety of switching from originator to biosimilar infliximab in patients with Behçet's disease. Internal and Emergency Medicine, 2019, 14, 719-722.	2.0	13
44	Perioperative myocardial infarction in elderly patients with hip fracture. Is there a role for early coronary angiography?. International Journal of Cardiology, 2019, 284, 1-5.	1.7	13
45	Vascular Behçet's syndrome: an update. Internal and Emergency Medicine, 2019, 14, 645-652.	2.0	99
46	Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. Nature Reviews Cardiology, 2019, 16, 113-130.	13.7	73
47	Position paper of the Italian Society of Internal Medicine (SIMI) on prophylaxis and treatment of venous thromboembolism in patients with cancer. Internal and Emergency Medicine, 2019, 14, 21-38.	2.0	13
48	Adalimumabâ€Based Treatment Versus Diseaseâ€Modifying Antirheumatic Drugs for Venous Thrombosis in Behçet's Syndrome. Arthritis and Rheumatology, 2018, 70, 1500-1507.	5.6	57
49	Management of idiopathic recurrent pericarditis in adults and in children: a role for IL-1 receptor antagonism. Internal and Emergency Medicine, 2018, 13, 475-489.	2.0	48
50	Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies. Annals of Neurology, 2018, 83, 283-294.	5.3	160
51	The vexed question of whether or not to measure levels of direct oral anticoagulants before surgery or invasive procedures. Internal and Emergency Medicine, 2018, 13, 1029-1036.	2.0	27
52	A focus on direct oral anticoagulants: "old―and possible new indications and efforts for a better clinical management. Internal and Emergency Medicine, 2018, 13, 985-988.	2.0	3
53	The association of adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) with cardiovascular disease in subjects with antiphospholipid antibodies. Atherosclerosis, 2018, 278, 60-65.	0.8	33
54	Atrial fibrillation in athletes: From epidemiology to treatment in the novel oral anticoagulants era. Journal of Cardiology, 2018, 72, 269-276.	1.9	8

#	Article	IF	CITATIONS
55	Impact of cardiovascular and immunologic variables on subclinical carotid atherosclerosis in subjects with anti-phospholipid antibodies. Data in Brief, 2018, 19, 1799-1803.	1.0	7
56	Sirt1 Protects against Oxidative Stress-Induced Apoptosis in Fibroblasts from Psoriatic Patients: A New Insight into the Pathogenetic Mechanisms of Psoriasis. International Journal of Molecular Sciences, 2018, 19, 1572.	4.1	49
57	Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood, 2018, 132, 1365-1371.	1.4	573
58	Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases. Current Cardiology Reports, 2018, 20, 61.	2.9	29
59	The left atrial appendage: from embryology to prevention of thromboembolism. European Heart Journal, 2017, 38, ehw159.	2.2	53
60	Longâ€ŧerm efficacy and safety of anakinra in a patient with Behçet's disease and concomitant tuberculosis infection. International Journal of Dermatology, 2017, 56, 218-220.	1.0	17
61	β2 Glycoprotein I Recognition Drives Th1 Inflammation in Atherosclerotic Plaques of Patients with Primary Antiphospholipid Syndrome. Journal of Immunology, 2017, 198, 2640-2648.	0.8	34
62	Italian intersociety consensus on DOAC use in internal medicine. Internal and Emergency Medicine, 2017, 12, 387-406.	2.0	44
63	Impact of residual pulmonary obstruction on the long-term outcome of patients with pulmonary embolism. European Respiratory Journal, 2017, 49, 1601980.	6.7	89
64	Erythrocyte Membrane Fluidity Alterations in Sudden Sensorineural Hearing Loss Patients: The Role of Oxidative Stress. Thrombosis and Haemostasis, 2017, 117, 2334-2345.	3.4	24
65	The Different Functional Distribution of "Not Effector―T Cells (Treg/Tnull) in Colorectal Cancer. Frontiers in Immunology, 2017, 8, 1900.	4.8	39
66	Apolipoprotein(a) Kringle-IV Type 2 Copy Number Variation Is Associated with Venous Thromboembolism. PLoS ONE, 2016, 11, e0149427.	2.5	24
67	To share or not to share, the dilemma is going to be solved. Internal and Emergency Medicine, 2016, 11, 771-772.	2.0	0
68	Obituary. Internal and Emergency Medicine, 2016, 11, 1153-1153.	2.0	0
69	Cytotoxic Th1 and Th17 cells infiltrate the intestinal mucosa of Behcet patients and exhibit high levels of TNF-α in early phases of the disease. Medicine (United States), 2016, 95, e5516.	1.0	43
70	Tocilizumab-induced exacerbation of mucosal ulcers in a patient with multi-refractory Behçet׳s disease. Seminars in Arthritis and Rheumatism, 2016, 46, e1-e2.	3.4	25
71	Sharing data of clinical trials. European Journal of Internal Medicine, 2016, 33, e25-e26.	2.2	0
72	SLE Pathogenesis: From Apoptosis to Lymphocyte Activation. Rare Diseases of the Immune System, 2016, , 23-34.	0.1	1

#	Article	IF	CITATIONS
73	Favorable pregnancy outcome in a patient with systemic lupus erythematosus treated with belimumab: A confirmation report. Seminars in Arthritis and Rheumatism, 2016, 45, e26-e27.	3.4	18
74	Erythrocyte oxidative stress is associated with cell deformability in patients with retinal vein occlusion. Journal of Thrombosis and Haemostasis, 2016, 14, 2287-2297.	3.8	42
75	Intra-tumoral IFN-Î ³ -producing Th22 cells correlate with TNM staging and the worst outcomes in pancreatic cancer. Clinical Science, 2016, 130, 247-258.	4.3	29
76	Comparison between different <scp>D</scp> â€ <scp>D</scp> imer cutoff values to assess the individual risk of recurrent venous thromboembolism: analysis of results obtained in the <scp>DULCIS</scp> study. International Journal of Laboratory Hematology, 2016, 38, 42-49.	1.3	464
77	Autoantibodies against β1â€Adrenergic Receptors: Response to Cardiac Resynchronization Therapy and Renal Function. PACE - Pacing and Clinical Electrophysiology, 2016, 39, 65-72.	1.2	3
78	Intracerebral hemorrhage score in patients with spontaneous intracerebral hemorrhage pretreated and not treated with antithrombotics. Neurology and Clinical Neuroscience, 2016, 4, 169-175.	0.4	2
79	Thrombosis in Autoimmune Diseases: A Role for Immunosuppressive Treatments?. Seminars in Thrombosis and Hemostasis, 2016, 42, 650-661.	2.7	22
80	Peripheral ENO1-specific T cells mirror the intratumoral immune response and their presence is a potential prognostic factor for pancreatic adenocarcinoma. International Journal of Oncology, 2016, 49, 393-401.	3.3	23
81	Internal and Emergency Medicine from a 2016 perspective. Internal and Emergency Medicine, 2016, 11, 287-287.	2.0	Ο
82	Chronic disease in the ethnic minority and migrant groups: time for a paradigm shift in Europe. Internal and Emergency Medicine, 2016, 11, 295-297.	2.0	13
83	Assessment of the Effects of Antithrombotic Drugs. , 2016, , 173-192.		Ο
84	General Aspects of Platelet Function Tests. , 2016, , 35-58.		0
85	Neutrophil Activation Promotes Fibrinogen Oxidation and Thrombus Formation in Behçet Disease. Circulation, 2016, 133, 302-311.	1.6	125
86	Efficacy and safety profile of anti-interleukin-1 treatment in Behçet's disease: a multicenter retrospective study. Clinical Rheumatology, 2016, 35, 1281-1286.	2.2	95
87	Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults. Blood Transfusion, 2016, 14, 23-65.	0.4	78
88	Novel oral anticoagulants in atrial fibrillation. Journal of Cardiovascular Medicine, 2015, 16, 512-519.	1.5	10
89	Gastric cancer and the epoch of immunotherapy approaches. World Journal of Gastroenterology, 2015, 21, 5778-5793.	3.3	80
90	Atrial fibrillation and its influence on stroke risk. Research Reports in Clinical Cardiology, 2015, , 11.	0.2	0

#	Article	IF	CITATIONS
91	Behçet's syndrome patients exhibit specific microbiome signature. Autoimmunity Reviews, 2015, 14, 269-276.	5.8	195
92	Microparticles: Bridging the Gap between Autoimmunity and Thrombosis. Seminars in Thrombosis and Hemostasis, 2015, 41, 413-422.	2.7	34
93	First report of <i>FIP1L1-PDGFRα</i> -positive eosinophilic granulomatosis with polyangiitis : Fig. 1. Rheumatology, 2015, 54, 1751-1753.	1.9	13
94	Antithrombotic drugs, patient characteristics, and gastrointestinal bleeding: Clinical translation and areas of research. Blood Reviews, 2015, 29, 335-343.	5.7	24
95	Thrombosis in vasculitis: from pathogenesis to treatment. Thrombosis Journal, 2015, 13, 15.	2.1	112
96	News for 2015. Internal and Emergency Medicine, 2015, 10, 537-537.	2.0	0
97	A new cytofluorimetric approach to evaluate the circulating microparticles in subjects with antiphospholipid antibodies. Thrombosis Research, 2015, 136, 1252-1258.	1.7	23
98	An Approach to Differential Diagnosis of Antiphospholipid Antibody Syndrome and Related Conditions. Scientific World Journal, The, 2014, 2014, 1-8.	2.1	19
99	Pancreatic cancer: Role of the immune system in cancer progression and vaccine-based immunotherapy. Human Vaccines and Immunotherapeutics, 2014, 10, 3354-3368.	3.3	85
100	Anti-TNF-α agents in vascular Behçet's disease. Expert Review of Cardiovascular Therapy, 2014, 12, 415-416.	1.5	5
101	Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedside. Autoimmunity Highlights, 2014, 5, 33-45.	3.9	32
102	Behçet's syndrome pathophysiology and potential therapeutic targets. Internal and Emergency Medicine, 2014, 9, 257-265.	2.0	54
103	Residual perfusion defects in patients with pulmonary embolism are related to impaired fibrinolytic capacity. Thrombosis Research, 2014, 134, 737-741.	1.7	18
104	Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A â€~state-of-the-art' paper. European Heart Journal, 2014, 35, 2213-2223.	2.2	78
105	Cardiovascular oncology: a new discipline inside internal medicine?. Internal and Emergency Medicine, 2014, 9, 359-364.	2.0	8
106	Ensuring medication adherence with direct oral anticoagulant drugs. Thrombosis Research, 2014, 133, 699-704.	1.7	39
107	Hyperhomocysteinemia in patients with pulmonary embolism is associated with impaired plasma fibrinolytic capacity. Journal of Thrombosis and Thrombolysis, 2014, 38, 45-49.	2.1	10
108	The role of inherited thrombophilia in patients with isolated pulmonary embolism: A systematic review and a meta-analysis of the literature. Thrombosis Research, 2014, 134, 84-89.	1.7	12

#	Article	IF	CITATIONS
109	Cardiovascular Issues: Aneurysms and Pseudoaneurysms, Thrombosis, Atherosclerosis, and Cardiac Involvement. Rare Diseases of the Immune System, 2014, , 125-135.	0.1	3
110	Pharmacological prevention of venous thromboembolism in orthopaedic surgery. Clinical Cases in Mineral and Bone Metabolism, 2014, 11, 192-5.	1.0	7
111	A new case of idiopathic recurrent acute pericarditis due to R104Q mutation in TNFRSF1A successfully treated with anakinra: expanding the questions. Clinical and Experimental Rheumatology, 2014, 32, 297.	0.8	5
112	Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions. Cancer Immunology, Immunotherapy, 2013, 62, 1249-1260.	4.2	102
113	ll Italian intersociety consensus statement on antithrombotic prophylaxis in orthopaedics and traumatology. Journal of Orthopaedics and Traumatology, 2013, 14, 1-13.	2.3	30
114	Consenso intersocietario sulla profilassi antitrombotica in chirurgia protesica dell'anca e del ginocchio e nelle fratture del collo femorale: aggiornamento 2013. LO SCALPELLO-OTODI Educational, 2013, 27, 161-169.	0.1	0
115	Perioperative assessment of platelet function by Thromboelastograph® Platelet Mappingâ,,¢ in cardiovascular patients undergoing non-cardiac surgery. Journal of Thrombosis and Thrombolysis, 2013, 35, 23-30.	2.1	34
116	Higher uric acid levels are associated with better functional recovery in elderly patients receiving cardiac rehabilitation. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 1210-1215.	2.6	10
117	Improving the use of direct oral anticoagulants in atrial fibrillation. European Journal of Internal Medicine, 2013, 24, 288-294.	2.2	11
118	Evaluation of the prevalence of severe hyperhomocysteinemia in adult patients with thrombosis who underwent screening for thrombophilia. Thrombosis Research, 2013, 132, 681-684.	1.7	16
119	FRI0348â€Biological treatment of behçet's disease according to different clinical "phenotypes― a retrospective study on 90 patients. Annals of the Rheumatic Diseases, 2013, 72, A491.3-A492.	0.9	0
120	What Is Recent in Pancreatic Cancer Immunotherapy?. BioMed Research International, 2013, 2013, 1-14.	1.9	19
121	Systemic Lupus Erythematosus: Immunopathogenesis and Novel Therapeutic Targets. International Journal of Immunopathology and Pharmacology, 2013, 26, 585-596.	2.1	12
122	Clinical Judgment When Using Coagulation Tests during Direct Oral Anticoagulant Treatment: A Concise Review. Seminars in Thrombosis and Hemostasis, 2013, 39, 840-846.	2.7	22
123	Vascular Behçet's disease: new insights in the management of thrombosis. Expert Review of Cardiovascular Therapy, 2013, 11, 1583-1585.	1.5	12
124	The Shc family protein adaptor, Rai, acts as a negative regulator of Th17 and Th1 cell development. Journal of Leukocyte Biology, 2013, 93, 549-559.	3.3	12
125	<i>Helicobacter Pylori</i> HP0175 Promotes the Production of IL-23, IL-6, IL-1Î ² and TGF-Î ² . European Journal of Inflammation, 2013, 11, 261-268.	0.5	7
126	The influence of factor V Leiden and G20210A prothrombin mutation on the presence of residual vein obstruction after idiopathic deep-vein thrombosis of the lower limbs. Thrombosis and Haemostasis, 2013, 109, 510-516.	3.4	7

#	Article	IF	CITATIONS
127	Perioperative Handling of Antiplatelet Drugs. A Critical Appraisal. Current Drug Targets, 2013, 14, 880-888.	2.1	28
128	Fibrinolytic inhibitors and fibrin characteristics determine a hypofibrinolytic state in patients with pulmonary embolism. Thrombosis and Haemostasis, 2013, 109, 565-567.	3.4	6
129	Location of venous thrombosis in patients with FVL or prothrombin G20210A mutations: Systematic review and meta-analysis. Thrombosis and Haemostasis, 2013, 110, 191-194.	3.4	7
130	Risk of recurrence in patients with pulmonary embolism: Predictive role of D-dimer and of residual perfusion defects on lung scintigraphy. Thrombosis and Haemostasis, 2013, 109, 181-186.	3.4	29
131	Direct oral anticoagulants for secondary prevention in patients with non-valvular atrial fibrillation. Italian Journal of Medicine, 2013, 7, 8.	0.3	3
132	Multiple Sclerosis: The Role of Cytokines in Pathogenesis and in Therapies. International Journal of Molecular Sciences, 2012, 13, 13438-13460.	4.1	67
133	T Cells in Gastric Cancer: Friends or Foes. Clinical and Developmental Immunology, 2012, 2012, 1-10.	3.3	40
134	The Thrombophilic Pattern of Different Clinical Manifestations of Venous Thromboembolism: A Survey of 443 Cases of Venous Thromboembolism. Seminars in Thrombosis and Hemostasis, 2012, 38, 230-234.	2.7	18
135	<i>Helicobacter pylori</i> : usefulness of an empirical fourth-line rifabutin-based regimen. Expert Review of Gastroenterology and Hepatology, 2012, 6, 437-439.	3.0	9
136	<i>Chlamydophila pneumoniae</i> phospholipase D (CpPLD) drives Th17 inflammation in human atherosclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 1222-1227.	7.1	53
137	Cardiovascular risk assessment beyond Systemic Coronary Risk Estimation. Journal of Hypertension, 2012, 30, 1056-1064.	0.5	86
138	Filling the gap between science & clinical practice: Prevention of stroke recurrence. Thrombosis Research, 2012, 129, 3-8.	1.7	14
139	A hypercoagulable and hypofibrinolytic state is detectable by global methods in patients with retinal vein occlusion. Atherosclerosis, 2012, 224, 97-101.	0.8	11
140	Efficacia e sicurezza dei nuovi farmaci anticoagulanti orali rispetto al warfarin nella profilassi cardioembolica del paziente con fibrillazione atriale non valvolare. Più luci che ombre. Italian Journal of Medicine, 2012, 6, 153-169.	0.3	0
141	Prevention of venous thromboembolism in patients with cancer: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)1. Thrombosis Research, 2012, 129, e171-e176.	1.7	46
142	Incidence and characteristics of asymptomatic distal deep vein thrombosis unexpectedly found at admission in an Internal Medicine setting. Thrombosis Research, 2012, 130, 591-595.	1.7	15
143	Fibrinolysis alterations in infertile women during controlled ovarian stimulation: Influence of BMI and genetic components. Thrombosis Research, 2012, 130, 919-924.	1.7	10
144	ll consensus intersocietario sulla profilassi antitrombotica in ortopedia e traumatologia. LO SCALPELLO-OTODI Educational, 2012, 26, 160-170.	0.1	1

#	Article	IF	CITATIONS
145	Helicobacter pylori management in primary care. Internal and Emergency Medicine, 2012, 7, 297-298.	2.0	3
146	The risk stratification in atrial fibrillation. Internal and Emergency Medicine, 2012, 7, 233-240.	2.0	7
147	The negative predictive value of D-dimer on the risk of recurrent venous thromboembolism in patients with multiple previous events: A prospective cohort study (the PROLONG PLUS study). American Journal of Hematology, 2012, 87, 713-715.	4.1	8
148	Bringing new players into the field: onco-pharmacovigilance in the era of cardio-oncology. Internal and Emergency Medicine, 2012, 7, 99-101.	2.0	12
149	Role of factorÂV Leiden or G20210A prothrombin mutation in patients with symptomatic pulmonary embolism and deep vein thrombosis: a metaâ€analysis of the literature. Journal of Thrombosis and Haemostasis, 2012, 10, 732-737.	3.8	22
150	Pulmonary fibrosis and lymphocytic alveolitis associated with triple antiphospholipid antibody positivity: a diagnostic puzzle. Clinical and Experimental Rheumatology, 2012, 30, 806.	0.8	4
151	Light Transmittance Aggregometry Induced by Different Concentrations of Adenosine Diphosphate to Monitor Clopidogrel Therapy: A Methodological Study. Therapeutic Drug Monitoring, 2011, 33, 94-98.	2.0	16
152	ATHEROSCLEROTIC AND THROMBOPHILIC RISK FACTORS IN PATIENTS WITH ISCHEMIC CENTRAL RETINAL VEIN OCCLUSION. Retina, 2011, 31, 724-729.	1.7	29
153	The Practical Management of Intracerebral Hemorrhage Associated with Oral Anticoagulant Therapy. International Journal of Stroke, 2011, 6, 228-240.	5.9	46
154	Italian intersociety consensus statement on antithrombotic prophylaxis in hip and knee replacement and in femoral neck fracture surgery. Journal of Orthopaedics and Traumatology, 2011, 12, 69-76.	2.3	21
155	Retinal vein occlusions: a review for the internist. Internal and Emergency Medicine, 2011, 6, 307-314.	2.0	55
156	Prevention of Venous Thromboembolism in Medical Patients with Thrombocytopenia or with Platelet Dysfunction: A Review of the Literature. Seminars in Thrombosis and Hemostasis, 2011, 37, 267-274.	2.7	44
157	Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study. Blood, 2010, 115, 481-488.	1.4	134
158	Incidence of recurrent venous thromboembolism and of chronic thromboembolic pulmonary hypertension in patients after a first episode of pulmonary embolism. Journal of Thrombosis and Thrombolysis, 2010, 30, 294-299.	2.1	90
159	Sex, age and normal postâ€anticoagulation Dâ€dimer as risk factors for recurrence after idiopathic venous thromboembolism in the Prolong study extension. Journal of Thrombosis and Haemostasis, 2010, 8, 1933-1942.	3.8	35
160	A severe case of warfarin–canrenoate interaction: a role for genetic predisposition?. British Journal of Haematology, 2010, 150, 482-483.	2.5	3
161	Comorbidities, alone and in combination with D-dimer, as risk factors for recurrence after a first episode of unprovoked venous thromboembolism in the extended follow-up of the PROLONG study. Thrombosis and Haemostasis, 2010, 103, 1152-1160.	3.4	15
162	Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients. Thrombosis and Haemostasis, 2010, 104, 587-292.	3.4	64

#	Article	IF	CITATIONS
163	Homocysteine in Vascular Behcl§et Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 2067-2074.	2.4	41
164	Fibrin Resistance to Lysis in Patients with Pulmonary Hypertension Other Than Thromboembolic. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 992-996.	5.6	60
165	High lipoprotein (a) levels are associated with an increased risk of retinal vein occlusion. Atherosclerosis, 2010, 210, 278-281.	0.8	29
166	Assessment of Fibrinolytic Activity by Measuring the Lysis Time of a Tissue Factor-induced Clot: A Feasibility Evaluation. Clinical and Applied Thrombosis/Hemostasis, 2010, 16, 337-344.	1.7	12
167	Behcet's Disease as a Model of Venous Thrombosis~!2009-11-07~!2009-12-07~!2010-02-22~!. Open Cardiovascular Medicine Journal, 2010, 4, 71-77.	0.3	47
168	Efficacy and safety of new oral anticoagulants in prophylaxis and treatment of venous thromboembolism. Reviews in Health Care, 2010, 1, 7-26.	0.1	1
169	Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment. Thrombosis and Haemostasis, 2009, 101, 938-942.	3.4	91
170	Stroke risk in atrial fibrillation patients on warfarin. Thrombosis and Haemostasis, 2009, 101, 367-372.	3.4	48
171	Assessment of Platelet Function on Whole Blood by Multiple Electrode Aggregometry in High-Risk Patients With Coronary Artery Disease Receiving Antiplatelet Therapy. American Journal of Clinical Pathology, 2009, 131, 834-842.	0.7	107
172	Assessment of Platelet Function in Whole Blood by Multiple Electrode Aggregometry: Transport of Samples Using a Pneumatic Tube SystemThe Authors' Reply. American Journal of Clinical Pathology, 2009, 132, 802-804.	0.7	12
173	Improving Antithrombotic Management in Patients With Atrial Fibrillation: Current Status and Perspectives. Seminars in Thrombosis and Hemostasis, 2009, 35, 527-542.	2.7	27
174	Different Models for Oral Anticoagulation Management May Be Applied Provided That Minimal Assistance Criteria Are Fulfilled: An Italian Experience. Seminars in Thrombosis and Hemostasis, 2009, 35, 568-573.	2.7	2
175	The Role of D-dimer Testing in Patients with Suspected Venous Thromboembolism. Seminars in Thrombosis and Hemostasis, 2009, 35, 050-059.	2.7	49
176	Standardized Low–Molecular-Weight Heparin Bridging Regimen in Outpatients on Oral Anticoagulants Undergoing Invasive Procedure or Surgery. Circulation, 2009, 119, 2920-2927.	1.6	133
177	Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment. American Journal of Hematology, 2009, 84, 584-588.	4.1	56
178	Evaluation of traditional and emerging cardiovascular risk factors in patients with non-arteritic anterior ischemic optic neuropathy: a case-control study. Graefe's Archive for Clinical and Experimental Ophthalmology, 2009, 247, 693-697.	1.9	45
179	Cerebral venous thrombosis treated with enoxaparin in an IUGR neonate with DIC. Child's Nervous System, 2009, 25, 899-902.	1.1	1
180	Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study. Journal of Thrombosis and Thrombolysis, 2009, 28, 381-388.	2.1	32

#	Article	IF	CITATIONS
181	Perioperative handling of patients on antiplatelet therapy with need for surgery. Internal and Emergency Medicine, 2009, 4, 279-288.	2.0	74
182	The quality of anticoagulation on functional outcome and mortality for TIA/stroke in atrial fibrillation patients. International Journal of Cardiology, 2009, 132, 109-113.	1.7	15
183	Vascular and connective tissue features in 5 Italian patients with homocystinuria. International Journal of Cardiology, 2009, 134, 251-254.	1.7	7
184	Bleeding Risk During Oral Anticoagulation in Atrial Fibrillation Patients Older Than 80 Years. Journal of the American College of Cardiology, 2009, 54, 999-1002.	2.8	115
185	Stroke risk in atrial fibrillation patients on warfarin. Predictive ability of risk stratification schemes for primary and secondary prevention. Thrombosis and Haemostasis, 2009, 101, 367-72.	3.4	14
186	Combination of Dâ€dimer, F1+2 and residual vein obstruction as predictors of VTE recurrence in patients with first VTE episode after OAT withdrawal. Journal of Thrombosis and Haemostasis, 2008, 6, 708-710.	3.8	52
187	Retrievable vena cava filters: Key considerations. Thrombosis Research, 2008, 122, 442-449.	1.7	37
188	Role of glycoprotein Ia gene polymorphisms in determining platelet function in myocardial infarction patients undergoing percutaneous coronary intervention on dual antiplatelet treatment. Atherosclerosis, 2008, 196, 341-348.	0.8	32
189	Low vitamin B6 and folic acid levels are associated with retinal vein occlusion independently of homocysteine levels. Atherosclerosis, 2008, 198, 223-227.	0.8	43
190	Atherosclerotic and Thrombophilic Risk Factors in Patients with Recurrent Central Retinal Vein Occlusion. European Journal of Ophthalmology, 2008, 18, 233-238.	1.3	23
191	Venous Thromboembolism Prevention in Patients with Heart Failure: An Often Neglected Issue. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2007, 36, 69-74.	0.3	9
192	Oral Factor Xa Inhibitors for Venous Thromboembolism Prevention in Major Orthopedic Surgery: A Review. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2007, 36, 217-226.	0.3	3
193	Comparison of Different Methods to Evaluate the Effect of Aspirin on Platelet Function in High-Risk Patients With Ischemic Heart Disease Receiving Dual Antiplatelet Treatment. American Journal of Clinical Pathology, 2007, 128, 143-149.	0.7	54
194	Cardiovascular and thrombophilic risk factors in patients with retinal artery occlusion. Blood Coagulation and Fibrinolysis, 2007, 18, 321-326.	1.0	32
195	Risk of bleeding in very old atrial fibrillation patients on warfarin: Relationship with ageing and CHADS2 score. Thrombosis Research, 2007, 121, 347-352.	1.7	82
196	Lipoprotein (a) and Venous Thromboembolism in Adults: A Meta-Analysis. American Journal of Medicine, 2007, 120, 728-733.	1.5	78
197	Role of haemorheological factors in patients with retinal vein occlusion. Thrombosis and Haemostasis, 2007, 98, 1215-1219.	3.4	22
198	Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy. Thrombosis and Haemostasis, 2007, 98, 844-851.	3.4	43

12

#	Article	IF	CITATIONS
199	Different methodologies for evaluating the effect of clopidogrel on platelet function in highâ€risk coronary artery disease patients. Journal of Thrombosis and Haemostasis, 2007, 5, 1839-1847.	3.8	180
200	Prevention and treatment of venous thromboembolism in the elderly patient. Clinical Interventions in Aging, 2007, 2, 237-46.	2.9	13
201	Role of haemorheological factors in patients with retinal vein occlusion. Thrombosis and Haemostasis, 2007, 98, 1215-9.	3.4	5
202	TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit. Thrombosis Research, 2006, 118, 495-500.	1.7	18
203	Renal transplant recipients are at high risk for both symptomatic and asymptomatic deep vein thrombosis. Journal of Thrombosis and Haemostasis, 2006, 4, 988-992.	3.8	53
204	Prophylaxis and treatment of venous thromboembolism in patients with cancer: an update. Internal and Emergency Medicine, 2006, 1, 273-278.	2.0	5
205	An unusual case of pulmonary hypertension in a young male. Internal and Emergency Medicine, 2006, 1, 127-132.	2.0	1
206	Hyperviscosity as a Possible Risk Factor for Cerebral Ischemic Complications in Atrial Fibrillation Patients. American Journal of Cardiology, 2006, 97, 1745-1748.	1.6	29
207	Usefulness of Aspirin Resistance After Percutaneous Coronary Intervention for Acute Myocardial Infarction in Predicting One-Year Major Adverse Coronary Events. American Journal of Cardiology, 2006, 98, 1156-1159.	1.6	95
208	Erythrocyte deformability and white blood cell count are associated with aspirin resistance in high-risk vascular patients. Clinical Hemorheology and Microcirculation, 2006, 35, 175-81.	1.7	25
209	High Rate of Recurrence in Renal Transplant Recipients after a First Episode of Venous Thromboembolism. Transplantation, 2005, 80, 789-793.	1.0	26
210	Cardiovascular and thrombophilic risk factors for idiopathic sudden sensorineural hearing loss. Journal of Thrombosis and Haemostasis, 2005, 3, 929-934.	3.8	108
211	Relevance of post-methionine homocysteine and lipoprotein (a) in evaluating the cardiovascular risk in young CAD patients. European Journal of Clinical Investigation, 2005, 35, 1-7.	3.4	1
212	Molecular diversity and thrombotic risk in protein S deficiency: The PROSIT study. Human Mutation, 2005, 25, 259-269.	2.5	48
213	PAI-1 and homocysteine, but not lipoprotein (a) and thrombophilic polymorphisms, are independently associated with the occurrence of major adverse cardiac events after successful coronary stenting. Heart, 2005, 92, 377-381.	2.9	46
214	Culprit Factors for the Failure of Well-Conducted Warfarin Therapy to Prevent Ischemic Events in Patients With Atrial Fibrillation. Stroke, 2005, 36, 2159-2163.	2.0	65
215	eNOS Gene Affects Red Cell Deformability: Role of T-786C, G894T, and 4a/4b Polymorphisms. Clinical and Applied Thrombosis/Hemostasis, 2005, 11, 481-488.	1.7	14
216	Venous thromboembolism prophylaxis in medical patients: Future perspectives. Thrombosis Research, 2005, 116, 365-375.	1.7	11

#	Article	IF	CITATIONS
217	Venous Thromboembolism in Renal Transplant Recipients: High Rate of Recurrence. Transplantation Proceedings, 2005, 37, 2493-2494.	0.6	15
218	Homocysteine-Lowering Therapy and Carotid Intima-Media Thickness in Renal Transplant Recipients. Transplantation Proceedings, 2005, 37, 2491-2492.	0.6	14
219	Thrombophilic risk factors for symptomatic peripheral arterial disease. Journal of Vascular Surgery, 2005, 41, 255-260.	1.1	55
220	Reduced erythrocyte deformability and hypercoagulability in idiopathic sudden sensorineural hearing loss. Clinical Hemorheology and Microcirculation, 2005, 33, 47-55.	1.7	13
221	Management of oral anticoagulant therapy in the real practice of an anticoagulation clinic: focus on atrial fibrillation. Blood Coagulation and Fibrinolysis, 2005, 16, 491-4.	1.0	4
222	Impaired fibrinolysis in retinal vein occlusion: a role for genetic determinants of PAI-1 levels. Thrombosis and Haemostasis, 2004, 92, 54-60.	3.4	36
223	Hyperhomocysteinemia and vitamin B6 deficiency: New risk markers for nonvalvular atrial fibrillation?. American Heart Journal, 2004, 148, 456-461.	2.7	49
224	Clotting activation after oral anticoagulant therapy discontinuation. Blood Coagulation and Fibrinolysis, 2004, 15, 221-225.	1.0	9
225	Point-of-Care Testing of Hemostasis in Cardiac Surgery. , 2003, 1, 1.		51
226	Asymptomatic excessive coumarin anticoagulation is a risk factor for thrombotic and bleeding complications of oral anticoagulant therapy. Journal of Thrombosis and Haemostasis, 2003, 1, 1840-1841.	3.8	11
227	ACE DD genotype: an independent predisposition factor to venous thromboembolism. European Journal of Clinical Investigation, 2003, 33, 642-647.	3.4	41
228	Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism. American Journal of Medicine, 2003, 115, 601-605.	1.5	91
229	Genetic determinants of fasting and post-methionine hyperhomocysteinemia in patients with retinal vein occlusion. Thrombosis Research, 2003, 110, 7-12.	1.7	38
230	Title is missing!. Blood Coagulation and Fibrinolysis, 2003, 14, 277-282.	1.0	2
231	Title is missing!. Blood Coagulation and Fibrinolysis, 2003, 14, 269-275.	1.0	8
232	Evaluation of a New Point-of-care Celite-activated Clotting Time Analyzer in Different Clinical Settings. Anesthesiology, 2003, 99, 54-59.	2.5	38
233	Low rate of bleeding and thrombotic complications of oral anticoagulant therapy independent of age in the real-practice of an anticoagulation clinic. Blood Coagulation and Fibrinolysis, 2003, 14, 269-275.	1.0	18
234	Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal-transplant recipients. Transplantation, 2003, 75, 1551-1555.	1.0	66

#	Article	IF	CITATIONS
235	Retinal vein thrombosis: risk factors, pathogenesis and therapeutic approach. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2002, 32, 308-311.	0.3	72
236	Need of more frequent International Normalized Ratio monitoring in elderly patients on long-term anticoagulant therapy after influenza vaccination. Blood Coagulation and Fibrinolysis, 2002, 13, 297-300.	1.0	23
237	Plasma and serum levels of D-dimer and their correlations with other hemostatic parameters in pregnancy. Thrombosis Research, 2002, 105, 257-262.	1.7	23
238	Cardiovascular and thrombophilic risk factors for central retinal vein occlusion. European Journal of Internal Medicine, 2002, 13, 163-169.	2.2	42
239	Tissue factor and tissue factor pathway inhibitor levels in unstable angina patients during short-term low-molecular-weight heparin administration. British Journal of Haematology, 2002, 117, 693-698.	2.5	11
240	Lipoprotein (a) and anticardiolipin antibodies are risk factors for clinically relevant restenosis after elective balloon percutaneous transluminal coronary angioplasty. Atherosclerosis, 2001, 154, 129-135.	0.8	21
241	Hyperhomocysteinemia in renal transplant patients as independent cause of endothelial damage and cardiovascular disease. Transplantation Proceedings, 2001, 33, 3682-3683.	0.6	5
242	Postprocedural PAI-1 Activity is a Risk Marker of Subsequent Clinical Restenosis in Patients Both with and without Stent Implantation After Elective Balloon PTCA. Thrombosis Research, 2001, 104, 181-186.	1.7	25
243	Activation of the immune system and coronary artery disease: the role of anti-endothelial cell antibodies. Atherosclerosis, 2001, 154, 429-436.	0.8	26
244	Thrombophilic Risk Factors in Patients with Central Retinal Vein Occlusion. Thrombosis and Haemostasis, 2001, 86, 722-726.	3.4	124
245	HIGH CYSTEINE LEVELS IN RENAL TRANSPLANT RECIPIENTS. Transplantation, 2001, 71, 746-751.	1.0	23
246	d -Dimer increase after percutaneous transluminal angioplasty and clinical recurrence after primary revascularization in acute myocardial infarction? A pilot study. Clinical and Experimental Medicine, 2001, 1, 219-224.	3.6	8
247	The Role of Cysteine and Homocysteine in Venous and Arterial Thrombotic Disease. American Journal of Clinical Pathology, 2001, 116, 56-60.	0.7	17
248	Hirudins for Prophylaxis and Treatment of Venous Thromboembolism. Seminars in Thrombosis and Hemostasis, 2001, 27, 543-550.	2.7	10
249	Thrombophilic risk factors in patients with central retinal vein occlusion. Thrombosis and Haemostasis, 2001, 86, 772-6.	3.4	35
250	Angiotensin-converting enzyme DD genotype, angiotensin type 1 receptor CC genotype, and hyperhomocysteinemia increase first-trimester fetal-loss susceptibility. Blood Coagulation and Fibrinolysis, 2000, 11, 657-662.	1.0	63
251	Angiotensin converting enzyme DD genotype affects the changes of plasma plasminogen activator inhibitor-1 activity after primary percutaneous transluminal coronary angioplasty in acute myocardial infarction patients. International Journal of Clinical and Laboratory Research, 2000, 30, 179-185.	1.0	11
252	Videolaparoscopic cholecystectomy induces a hemostasis activation of lower grade than does open surgery. Surgical Endoscopy and Other Interventional Techniques, 2000, 14, 170-174.	2.4	56

#	Article	IF	CITATIONS
253	Tissue Factor and Homocysteine Levels in Ischemic Heart Disease Are Associated with Angiographically Documented Clinical Recurrences after Coronary Angioplasty. Thrombosis and Haemostasis, 2000, 83, 826-832.	3.4	43
254	An increased thrombin generation is detectable for at least 1 week following elective percutaneous transluminal coronary angioplasty. Fibrinolysis and Proteolysis, 2000, 14, 253-260.	1.1	1
255	Effect of Temperature and Incubation Time on D-Dimer Serum Levels in Healthy Subjects. Thrombosis Research, 2000, 97, 513-517.	1.7	2
256	High prevalence of mild hyperhomocysteinemia in patients with abdominal aortic aneurysm. Journal of Vascular Surgery, 2000, 32, 531-536.	1.1	92
257	Tissue factor and homocysteine levels in ischemic heart disease are associated with angiographically documented clinical recurrences after coronary angioplasty. Thrombosis and Haemostasis, 2000, 83, 826-32.	3.4	4
258	Tissue Factor Reduction and Tissue Factor Pathway Inhibitor Release after Heparin Administration. Thrombosis and Haemostasis, 1999, 81, 589-593.	3.4	54
259	The pre-procedural platelet state predicts clinical recurrence after coronary angioplasty. International Journal of Clinical and Laboratory Research, 1999, 29, 145-149.	1.0	3
260	The influence of smoking on von Willebrand factor is already manifest in healthy adolescent females: the Floren-teen (Florence Teenager) Study. International Journal of Clinical and Laboratory Research, 1999, 29, 150-154.	1.0	10
261	World distribution of the T833C/844INS68 CBS in cis double mutation: a reliable anthropological marker. Human Genetics, 1999, 104, 126-129.	3.8	37
262	Impairment of early fibrinolytic activation after PTCA: a mechanism for restenosis-related clinical recurrence?. Fibrinolysis and Proteolysis, 1999, 13, 8-14.	1.1	6
263	Microheterogeneity in the Distribution of the 844ins68 in the Cystathionine β-Synthase Gene in Italy. Thrombosis Research, 1999, 94, 249-254.	1.7	14
264	Electrophysiologic procedures and activation of the hemostatic system. American Heart Journal, 1999, 138, 128-132.	2.7	30
265	Usefulness of Screening for Congenital or Acquired Hemostatic Abnormalities in Women with Previous Complicated Pregnancies. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1999, 29, 197-203.	0.3	22
266	Acquired Activated Protein C Resistance in Postmenopausal Women Is Dependent on Factor VIII:c Levels. American Journal of Clinical Pathology, 1999, 111, 769-772.	0.7	20
267	Role of platelet glycoprotein PLA1/A2 polymorphism in restenosis after percutaneous transluminal coronary angioplasty. American Journal of Cardiology, 1998, 82, 524-525.	1.6	27
268	Effect of low-dose heparin on fibrinogen levels in patients with chronic ischemic heart disease. International Journal of Clinical and Laboratory Research, 1998, 28, 170-173.	1.0	8
269	Evaluation of Clotting and Fibrinolytic Activation after Protracted Physical Exercise. Thrombosis Research, 1998, 89, 73-78.	1.7	71
270	Factor II 20210 G→A Polymorphism Associated to Factor V Leiden. Thrombosis Research, 1998, 89, 249-252.	1.7	6

#	Article	IF	CITATIONS
271	Low-Dose Heparin Pretreatment is not Able to Prevent Clotting Activation during Coronary Angiography. Thrombosis Research, 1998, 91, 151-153.	1.7	2
272	Effect of Medium-term Supplementation with a Moderate Dose of n-3 Polyunsaturated Fatty Acids on Blood Pressure in Mild Hypertensive Patients. Thrombosis Research, 1998, 91, 105-112.	1.7	82
273	Heterogeneity in World Distribution of the Thermolabile C677T Mutation in 5,10-Methylenetetrahydrofolate Reductase. American Journal of Human Genetics, 1998, 63, 917-920.	6.2	101
274	The High Prevalence of Thermolabile 5-10 Methylenetetrahydrofolate Reductase (MTHFR) in Italians Is not Associated to an Increased Risk for Coronary Artery Disease (CAD). Thrombosis and Haemostasis, 1998, 79, 727-730.	3.4	73
275	Elevated Tissue Factor and Tissue Factor Pathway Inhibitor Circulating Levels in Ischaemic Heart Disease Patients. Thrombosis and Haemostasis, 1998, 79, 495-499.	3.4	108
276	Cytokine Gene Expression in Human LPS- and IFNÎ ³ -stimulated Mononuclear Cells Is Inhibited by Heparin. Thrombosis and Haemostasis, 1998, 79, 959-962.	3.4	53
277	EFFECTS OF ESTROGEN REPLACEMENT THERAPY ON THROMBIN GENERATION. Thrombosis Research, 1997, 85, 185-193.	1.7	16
278	CHANGES IN LIPIDIC AND HEMOSTATIC PARAMETERS INDUCED BY TIBOLONE TREATMENT Thrombosis Research, 1997, 85, 273-278.	1.7	15
279	PERSISTENCE OF HEMOSTATIC ALTERATIONS IN PATIENTS AFFECTED BY CROHN'S DISEASE AFTER BOWEL SURGERY. Thrombosis Research, 1997, 87, 539-546.	1.7	18
280	Short-term ACE inhibition may influence exercise-induced changes in haemostasis in healthy subjects. Fibrinolysis and Proteolysis, 1997, 11, 187-192.	1.1	4
281	D-Dimer plasma levels during normal pregnancy measured by specific ELISA. International Journal of Clinical and Laboratory Research, 1997, 27, 65-67.	1.0	43
282	Prevalence of Factor V Leiden Mutation in Non-European Populations. Thrombosis and Haemostasis, 1997, 77, 329-331.	3.4	76
283	Different Distribution of the Double Mutant "T833C/68 bp Insertion―in Cystathionine β-Synthase Gene in Northern and Southern Italian Populations. Thrombosis and Haemostasis, 1997, 78, 1293-1293.	3.4	9
284	Acute T-Cell Activation Is Detectable in Unstable Angina. Circulation, 1997, 95, 1806-1812.	1.6	157
285	Hemostatic abnormalities in inflammatory bowel disease. Thrombosis Research, 1996, 82, 137-146.	1.7	92
286	Antiphospholipid antibodies and pregnancy disorders in women with insulin dependent diabetes. Thrombosis Research, 1996, 82, 207-216.	1.7	17
287	PLATELET AND BLOOD CLOTTING ACTIVATION IN PATIENTS WITH MITRAL VALVE PROLAPSE. Thrombosis Research, 1996, 83, 299-306.	1.7	22
288	MENOPAUSE AND RISK OF CARDIOVASCULAR DISEASE. Thrombosis Research, 1996, 84, 1-19.	1.7	25

#	Article	IF	CITATIONS
289	BLOOD CLOTTING ACTIVATION DURING NORMAL PREGNANCY. Thrombosis Research, 1996, 84, 199-202.	1.7	69
290	n-3 PUFA supplementation, monocyte PCA expression and interleukin-6 production. Prostaglandins Leukotrienes and Essential Fatty Acids, 1996, 54, 439-444.	2.2	45
291	Effect of n-3 polyunsaturated fatty acid intake on phospholipid fatty acid composition in plasma and erythrocytes. American Journal of Clinical Nutrition, 1996, 63, 925-932.	4.7	39
292	Relationship between plasma and platelet phospholipid fatty acid composition in healthy subjects. Platelets, 1996, 7, 69-73.	2.3	6
293	Fibrinogen and Factor Vllag in Healthy Adolescents: The Floren-teen (Florence Teenager) Study. Thrombosis and Haemostasis, 1996, 75, 778-781.	3.4	10
294	Fibrinogen and factor VIIag in healthy adolescents: the Floren-teen (Florence teenager) Study. Thrombosis and Haemostasis, 1996, 75, 778-81.	3.4	1
295	Exercise-induced tissue plasminogen activator increase: a role for metabolic acidosis. Fibrinolysis, 1995, 9, 363-367.	0.5	Ο
296	Fibrin generation and digestion in patients with angina pectoris. International Journal of Clinical and Laboratory Research, 1995, 25, 222-225.	1.0	2
297	Platelet activation and platelet lipid composition in pulmonary cancer. Prostaglandins Leukotrienes and Essential Fatty Acids, 1995, 53, 65-68.	2.2	29
298	Effect of n-3 fatty acid ethyl ester supplementation on fatty acid composition of the single platelet phospholipids and on platelet functions. Metabolism: Clinical and Experimental, 1995, 44, 562-569.	3.4	30
299	D-dimer concentrations during normal pregnancy, as measured by ELISA. Thrombosis Research, 1995, 78, 399-405.	1.7	98
300	D-Dimer in intra-uterine growth retardation and gestational hypertension. Thrombosis Research, 1995, 80, 89-92.	1.7	11
301	Effects of Amlodipine on Platelet Aggregation in Hypertensive Patients. Clinical Drug Investigation, 1995, 9, 255-259.	2.2	2
302	Physical exercise and hemostasis. International Journal of Clinical and Laboratory Research, 1994, 24, 125-131.	1.0	23
303	Evaluation of prothrombin F1+2 fragment after videolaparoscopic surgery. Thrombosis Research, 1994, 75, 219-222.	1.7	4
304	No changes in PAI-1 levels after four-month n-3 PUFA ethyl ester supplementation in healthy subjects. Thrombosis Research, 1994, 76, 237-244.	1.7	17
305	Euglobulin Lysis Time in Fresh and Stored Samples. American Journal of Clinical Pathology, 1994, 102, 794-796.	0.7	7
306	Age-related changes in the hemostatic system. International Journal of Clinical and Laboratory Research, 1993, 23, 1-3.	1.0	80

#	Article	IF	CITATIONS
307	Predictive value for thrombotic disease of plasminogen activator inhibitor-1 plasma levels. International Journal of Clinical and Laboratory Research, 1993, 23, 78-82.	1.0	6
308	Thrombin generation after physical exercise. Thrombosis Research, 1993, 69, 159-164.	1.7	38
309	Effect of Low-Dose Heparin Treatment on Fibrinolysis in Patients with Previous Myocardial Infarction. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1993, 23, 308-313.	0.3	3
310	Human prostacyclin platelet receptors in diabetes mellitus. Thrombosis Research, 1991, 63, 541-548.	1.7	16
311	In vitro effects of two novel calcium antagonists (nitrendipine and nisoldipine) on intraplatelet calcium redistribution, platelet aggregation and thromboxane A2 formation. Comparison with diltiazem, nifedipine and verapamil. Thrombosis Research, 1991, 63, 457-462.	1.7	21
312	Age-Related Changes in Red Blood Cell Lipids. Angiology, 1991, 42, 316-322.	1.8	17
313	Low-Dose Heparin as an Antithrombotic Agent. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1990, 20, 129-131.	0.3	1
314	Prostaglandins in squamous cell carcinoma of the larynx: Tumor and peritumor synthesis. Prostaglandins Leukotrienes and Essential Fatty Acids, 1990, 39, 53-57.	2.2	18
315	Relationship between classical FDP test and D-dimer assayed both by latex agglutination and ELISA. Thrombosis Research, 1990, 59, 207-212.	1.7	6
316	No signs of increased thrombin generation in menopause. Thrombosis Research, 1990, 58, 645-651.	1.7	13
317	Effects of calcium channel blockers on platelet aggregation and thromboxane A2 formation: An in vivo double blind randomized study. Thrombosis Research, 1990, 59, 531-539.	1.7	13
318	Sex related differences in platelet TXA2 generation. Prostaglandins Leukotrienes and Essential Fatty Acids, 1990, 40, 217-221.	2.2	19
319	Physiologic role of coronary PGl2 and PGE2 in modulating coronary vascular response to sympathetic stimulation. American Heart Journal, 1990, 119, 848-854.	2.7	15
320	Defective coronary prostaglandin modulation in anginal patients. American Heart Journal, 1990, 120, 12-21.	2.7	7
321	Markers of increased thrombin generation. Research in Clinic and Laboratory, 1990, 20, 217-225.	0.3	11
322	Ability of Whole Blood Aggregometer to Detect Platelet Hyperaggregability. American Journal of Clinical Pathology, 1989, 91, 159-164.	0.7	24
323	Red blood cell lipid alterations in type II diabetes mellitus. Thrombosis Research, 1989, 54, 751-758.	1.7	25
324	Evaluation of new methods for the selective measurement of fibrin and fibrinogen degradation products. Thrombosis Research, 1989, 56, 547-551.	1.7	19

#	Article	IF	CITATIONS
325	Altered membrane fatty acid composition and increased thromboxane A2 generation in platelets from patients with diabetes. Prostaglandins Leukotrienes and Essential Fatty Acids, 1989, 35, 15-23.	2.2	28
326	Hemostatic alterations during human immunodeficiency virus infection: A review. Research in Clinic and Laboratory, 1989, 19, 95-104.	0.3	2
327	Decrease in frequency of anginal episodes by control of thrombin generation with low-dose heparin: A controlled cross-over randomized study. American Heart Journal, 1988, 115, 60-67.	2.7	22
328	Radioimmunoassay of thromboxane B2 in plasma: Methodological modifications. Thrombosis Research, 1988, 51, 533-541.	1.7	3
329	Altered lipid composition and thromboxane A2 formation in platelets from patients affected by IIa hyperlipoproteinemia. Thrombosis Research, 1988, 50, 593-604.	1.7	29
330	Platelet synthesis of cyclooxygenase and lipoxygenase products in type I and type II diabetes. Prostaglandins Leukotrienes and Essential Fatty Acids, 1988, 31, 9-15.	2.2	17
331	Effect of Oral Treatment with Pantethine on Platelet and Plasma Phospholipids in IIa Hyperlipoproteinemia. Angiology, 1987, 38, 241-247.	1.8	14
332	Altered intraplatelet arachidonic acid metabolism during the acute state of unstable angina. Thrombosis Research, 1987, 46, 303-316.	1.7	10
333	Association between time of increased fibrinopeptide A levels in plasma and episodes of spontaneous angina: A controlled prospective study. American Heart Journal, 1987, 113, 672-678.	2.7	47
334	Blood velocity in the coronary artery circulation: Relation to thromboxane A2 levels in coronary sinus in patients with angiographically normal coronary arteries. Catheterization and Cardiovascular Diagnosis, 1987, 13, 162-166.	0.3	9
335	Impaired cardiac PGI2 and PGE2 biosynthesis in patients with angina pectoris. American Heart Journal, 1986, 112, 472-478.	2.7	13
336	Increased thromboxane a2 generation and altered membrane fatty acid composition in platelets from patients with active angina pectoris. Thrombosis Research, 1986, 44, 101-112.	1.7	22
337	Age related changes in platelet lipid composition. Thrombosis Research, 1986, 44, 427-437.	1.7	26
338	Factors Influencing Platelet Aggregation in Whole Blood. American Journal of Clinical Pathology, 1986, 86, 91-96.	0.7	63
339	Enhanced peripheral vasoconstrictor response and increased thromboxane A2 synthesis after the cold pressor test in patients with angina at rest Circulation, 1986, 73, 409-417.	1.6	22
340	Spontaneous and cold pressor test-induced prostaglandin biosynthesis by human heart. American Heart Journal, 1985, 110, 50-55.	2.7	10
341	Abnormal cardiocoronary thromboxane A2 production in patients with unstable angina. American Heart Journal, 1985, 109, 732-738.	2.7	28
342	Multicenter evaluation of a new chromogenic factor X assay in plasma of patients on oral anticoagulants. Thrombosis Research, 1980, 19, 493-502.	1.7	20

#	Article	IF	CITATIONS
343	Efficacy and safety of new oral anticoagulants compared with warfarin in cardioembolic prophylaxis of patients with non valvular atrial fibrillation. More lights than shadows. Italian Journal of Medicine, 0, , .	0.3	3